Novartis inks $925M Anthos takeover to buy back phase 3 clot-busting candidate
Tariffs raise concern among generic drugmakers, as advocacy groups seek exemptions
Wegovy and Ozempic stars dim amid overuse concerns
Ten years on, Roche jettisons InterMune and Esbriet in US
*please scroll down for all the latest news*
